Ovarian cancer

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…

This phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The st…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

Researchers are testing whether adding inhaled manganese chloride to standard chemotherapy and an anti-PD-1 immunotherapy can help people with advanced ovarian cancer that has worsened after at least two prior treatments. The trial enrolls about 120 participants and randomly assi…

This early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an ext…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…

This study tests whether a daily pill called isoquercetin, made from a plant compound, can reduce blood markers linked to clot risk in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal i…

This study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…

This Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…

This study compares two surgical approaches for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received chemotherapy before surgery. One group will have minimally invasive surgery (small incisions), and the other will have standard open surger…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study tests a new drug called SHR-A1811 combined with standard chemotherapy (carboplatin and bevacizumab) in 150 women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to find the safest dose and see if the combination shrinks tumors …

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This early-phase study tests a new drug called DT2216 combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the highest safe dose of DT2216 when given with paclitaxel. About 30…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This early-phase trial is testing a new treatment called B7-H3 CAR T cells for adults with ovarian cancer that has come back and no longer responds to platinum chemotherapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize an…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherap…

This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…

This early-phase trial is testing whether a personalized mRNA vaccine called NeoOVSV, given alongside standard chemotherapy and an immunotherapy drug, can safely help prevent ovarian cancer from returning after surgery. The vaccine is designed to train the immune system to recogn…

This early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…

This early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…

This phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…

This study looks at whether irreversible electroporation (IRE) can safely and effectively treat recurrent pelvic tumors in people who cannot have surgery, radiation, or other local treatments. IRE uses electrical pulses to destroy cancer cells without cutting or heating tissue. R…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This phase 2 trial tests whether combining disitamab vedotin, AK104, and bevacizumab can shrink tumors in people with recurrent or persistent clear cell ovarian cancer. Clear cell ovarian cancer is a rare and aggressive subtype that often stops responding to standard platinum-bas…

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This Phase 3 study tests whether a modified virus called Olvi-Vec, given with chemotherapy and bevacizumab, can help women with ovarian cancer that no longer responds to platinum drugs. About 186 participants will receive either the virus combination or standard chemotherapy. The…

This early-phase trial tests a technique called PIPAC, which turns liquid chemotherapy into a fine mist sprayed directly into the abdomen during a minimally invasive surgery. It aims to see if this approach is safe and causes fewer side effects than standard chemotherapy. The stu…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study looks at how well niraparib works as a first-line maintenance therapy for women with advanced ovarian cancer when used in everyday clinical practice. It will follow about 1,920 patients who have completed initial chemotherapy and are now taking niraparib to keep the ca…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…

This early-stage trial tests an investigational drug called NTB-928 in women with ovarian cancer that has come back or no longer responds to standard treatments. NTB-928 is designed to direct the body's immune T cells to attack cancer cells by targeting a protein called FRα. The …

This early-phase trial tests whether adding the drug lurbinectedin to two standard chemotherapy drugs (paclitaxel and bevacizumab) can better control platinum-resistant ovarian cancer. About 34 adults with advanced ovarian, fallopian tube, or peritoneal cancer will receive the co…

This study tests an experimental drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, peritoneal, or endometrial cancer. The trial has two parts: first to find the safest dose, then to see if the drug shrinks tumors. About 612 particip…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…

This study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…

This early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people with ovarian or endometrial cancer that has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 5…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take nirapa…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This phase 3 trial tests whether a denser weekly chemotherapy schedule (carboplatin every 3 weeks plus weekly paclitaxel) can help ovarian cancer patients whose tumors are not responding well to standard treatment. The study enrolls 250 adults with advanced ovarian cancer who hav…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This study tests whether giving heated chemotherapy directly into the abdomen during surgery is safe for women aged 70 and older with advanced ovarian cancer. The treatment, called NIPEC with carboplatin, is delivered at normal body temperature for 90 minutes right after the surg…

This early-stage trial is testing a new drug called AOH1996 in 92 adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The drug works by blocking a protein that cancer cells need to grow. The main goals are to fi…

This study tests whether women with advanced ovarian cancer who have had all visible tumor removed can safely receive only 3 cycles of chemotherapy instead of the standard 6, followed by a maintenance drug called niraparib. The goal is to see if the shorter chemo is just as effec…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This early-phase trial is testing an experimental oral drug called APG-2449 in people with advanced solid tumors, including certain lung cancers, mesothelioma, esophageal cancer, and ovarian cancer. APG-2449 is designed to block several proteins (FAK, ALK, and ROS1) that help can…

This early-phase trial tests a new drug called GP-2250 combined with the chemotherapy gemcitabine in people with advanced pancreatic cancer that has worsened after standard treatment. The main goal is to check safety and find the right dose. About 64 adults will take part, and re…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This Phase 2 study tests several immunotherapy drug combinations in women with platinum-resistant high-grade serous ovarian cancer, a type that no longer responds to standard chemotherapy. About 60 participants will receive one of five immunotherapy regimens to see which best shr…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…

This phase II trial tests the drug abemaciclib in people whose ovarian or endometrial cancer has returned and whose tumors have a specific genetic change (CDK4/6 pathway activation). Abemaciclib is a pill that blocks certain enzymes that cancer cells need to grow. The study will …

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or…

This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tu…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This study is testing whether a combination of two drugs, mirvetuximab soravtansine and olaparib, can help keep ovarian, peritoneal, or fallopian tube cancer from coming back after initial treatment. About 53 women with cancer that responded to platinum-based chemotherapy will re…

This study tests whether adding an experimental drug called TORL-1-23 to standard chemotherapy before surgery can help women with advanced ovarian cancer. About 60 participants with a specific tumor marker (CLDN6) will receive the combination, then undergo surgery. The goal is to…

This phase 2 trial investigates whether adding stereotactic body radiotherapy (SBRT) to the PARP inhibitor niraparib can improve control of ovarian cancer that has spread to a limited number of new spots after prior PARP inhibitor therapy. Participants will receive SBRT alone or …

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This trial tests a new experimental drug called CPI-0209 (Tulmimetostat) combined with the chemotherapy drug carboplatin in women whose ovarian cancer has returned but still responds to platinum-based treatments. The study aims to find the safest dose of CPI-0209 when given with …

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

This early-phase trial is testing how the antifungal drug itraconazole affects the levels of a new cancer drug, AZD5335, in the body. The study involves 24 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is …

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum chemotherapy. The main goals are to check safety and find the best dose. Researchers will also watch for signs that the drug shrinks tumors or sl…

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This phase 3 trial tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy can delay cancer progression better than bevacizumab alone in people with HER2-expressing advanced ovarian cancer. About 582 adults whose cancer has a specific prote…

This study tests an experimental drug called azenosertib (ZN-c3) in people with a specific type of ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy. The drug aims to shrink or control tumors by blocking a protein that cancer cells nee…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This trial tests whether placing a surgical mesh during abdominal closure can prevent incisional hernias in women undergoing ovarian cancer surgery. It also examines if a negative pressure wound dressing reduces infection risk. Participants are randomly assigned to one of four gr…

This phase 2 trial tests whether adding propranolol, a widely used beta-blocker, to standard chemotherapy before surgery can improve outcomes for women with advanced high-grade serous ovarian cancer. Participants receive propranolol pills alongside paclitaxel and carboplatin, fol…

This phase 2 trial is testing a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in women with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive two maintenance drugs (olaparib and pemb…

This trial investigates whether giving back a patient's own blood stem cells after chemotherapy can help their bone marrow recover faster. The study includes women aged 18–60 with recurrent or metastatic ovarian cancer who are scheduled for chemotherapy. The goal is to reduce sev…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This phase 2 trial is testing a combination of three drugs—ipalotinib, sunitinib, and olaparib—given before surgery to people with a specific type of advanced ovarian cancer (HRD-positive). The goal is to shrink tumors enough to allow complete removal during surgery. The study wi…

This study offers continued access to niraparib, a daily oral cancer drug, for up to 37 patients with ovarian or breast cancer who have already completed a prior niraparib trial and are still benefiting. The main goal is to monitor long-term safety, including side effects and cha…

This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize a…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…

This Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…

This early-phase trial tests a new type of immune cell therapy called CIML NK cells in 18 people with recurrent ovarian cancer that no longer responds to standard chemotherapy. The cells are taken from the patient, trained in a lab to better attack cancer, and then infused into t…

This early-stage trial is testing whether a patient's own tumor-fighting immune cells (called TILs) can be safely used to treat recurrent ovarian cancer. Researchers take a sample of the tumor, grow the immune cells in a lab, and then inject them back into the patient. Only 6 peo…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study compares a new barbed suture (SYMMCORA) with a standard one (V-Loc) for closing the vaginal cuff after laparoscopic hysterectomy. The goal is to see if the new suture reduces stitching time without increasing complications. About 132 women having elective laparoscopic …

This study looks at two different surgeries for advanced ovarian cancer that has spread to the bowel. One method removes only the tumor from the bowel, while the other removes a piece of the bowel along with the tumor. The goal is to see which approach helps patients live longer …

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalize…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in about 24 people whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if th…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, comb…

This study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at leas…

This early-phase trial is testing a new treatment for ovarian cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is to find a safe dose and see what side…

This study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of iron-containing nanoparticles that travel to the tumor, then a machine creates a magnetic field to heat the particles and da…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This early-stage trial tests a new treatment called EB-DUALNK for adults with ovarian cancer that has come back or not responded to standard therapies. The treatment uses specially designed natural killer (NK) cells that target two markers on cancer cells. After a short course of…

This study compares a new method called PIPAC, which delivers chemotherapy as a spray inside the abdomen, to standard treatment for advanced ovarian cancer. The goal is to see if PIPAC can better reduce the cancer before surgery. About 60 adults with stage IIIC-IVA ovarian cancer…

This study tests an experimental drug called SKB518, given alone or with chemotherapy, in 280 people with advanced ovarian, cervical, or endometrial cancers. The goal is to see if the drug can shrink tumors or slow cancer growth. Researchers will also monitor side effects.

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This study looks at whether removing enlarged lymph nodes in the chest area during surgery can help people with advanced ovarian cancer live longer without the cancer coming back. About 52 women with stage III or IV ovarian cancer will take part. The goal is to see if this extra …

This study tests whether a new version of the drug olaparib (DWZ2501) works as well as the current version (DWC202510) in women with advanced BRCA-mutated ovarian cancer. About 40 participants will take both versions at different times to compare drug levels and safety. The goal …

This phase II trial is testing whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, can control recurrent gynecological clear cell carcinoma better than standard chemotherapy. About 198 women with this rare cancer type will be randomly assigned to one o…

This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…

This phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see…

This early-stage trial tests a new treatment called THEO-260, a virus designed to infect and destroy cancer cells. It is given directly into the abdomen to 18 people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to find a safe d…

This study tests a drug called HLX43 in 190 people with advanced cervical or ovarian cancer that came back or spread after initial treatment. HLX43 is designed to deliver a toxin directly to cancer cells by targeting a protein called PD-L1. The goal is to see if it can shrink tum…

This phase 2 trial is testing whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 participants will take niraparib pills daily until their cancer grows or side effects become too much. …

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This phase 3 trial tests a new drug called SHR-A1811 against standard chemotherapy in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatment. The goal is to see if the new drug can slow cancer growth and improve s…

This Phase 2 trial tests whether trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, works better than standard chemotherapy for recurrent ovarian cancer that has stopped responding to PARP inhibitors. About 116 participants whose tumors express the HER2 protein w…

This phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 220 participants will be randomly assigned to receive either heated chemo plus standard tre…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This study tests a new treatment called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors like ovarian cancer. The goal is to see if it is safe and can shrink tumors. About 18 adults aged 18-70 with relapsed or metastat…

This study tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. About 44 participants will receive different doses of the virus through an IV to find a safe dose an…

This phase 2 trial tests whether combining surgery to remove visible tumor with heated chemotherapy delivered directly into the abdomen can help women whose mucinous ovarian cancer has returned. About 30 participants will receive this intensive treatment. The goal is to see how l…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: niraparib alone versus niraparib plus bevacizumab. The goal is to see which approach better delays cancer progression. About 390 participan…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This study tests a technique called acute normovolemic hemodilution (ANH) in 86 women having surgery for advanced ovarian cancer. Before surgery, some blood is removed and stored, then returned during or after the operation. The goal is to see if this reduces the need for donor b…

This clinical trial tests whether the experimental antibody COM701 can delay the return of ovarian cancer in people whose cancer has come back but still responds to platinum chemotherapy. About 60 participants will receive COM701 or a placebo every three weeks as maintenance ther…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This study tests a new drug called CapsuleX combined with cisplatin in 40 people whose ovarian cancer no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and how safe it is. Participants must have confirmed ovarian, fallopian…

This early-phase study tests a new personalized cell therapy called Innocell for people with recurrent epithelial ovarian cancer. The treatment uses a patient's own tumor tissue to create a custom immunotherapy. The main goals are to see if it is safe to give and if the body's im…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This early-stage trial is testing a virus called IVX037, which is injected directly into tumours to kill cancer cells. It is being studied alone and combined with an immunotherapy drug (sintilimab) in people with advanced colorectal, gastric, or ovarian cancers that have stopped …

This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adul…

This study tests a new treatment using specially engineered natural killer (NK) cells to fight ovarian cancer that has come back or not responded to standard therapies. The treatment is personalized: each participant's tumor is checked for three markers, and they receive NK cells…

This study tests a new drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, brain, pancreas, or skin cancer. The trial has two phases: first, finding the safest dose, then testing that dose in a larger group. About 80 participants will be …

This study tests adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) for people whose ovarian cancer has returned. The goal is to find a safe dose and see if the combination helps shrink tumors or slow cancer growth. About 72 participants with recurrent ova…

This study tests a new treatment for advanced ovarian cancer patients who have a lot of fluid in their belly (ascites) and have not responded to standard therapies. The treatment involves injecting special immune cells called SK-NK cells directly into the abdomen once a week for …

This study tests whether a PARP inhibitor combined with bevacizumab (Avastin) can delay cancer recurrence in people with advanced ovarian, fallopian-tube, or primary peritoneal cancer that has a specific DNA repair defect (HRD). About 120 participants will receive chemotherapy pl…

This study tests a comprehensive fitness and nutrition program (prehabilitation) given before major cancer surgery. It includes 148 patients with pancreatic, ovarian, kidney, or bladder cancer who are frail or pre-frail. Some patients get the program alone, others get it with che…

This early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and …

This study tests a new approach for advanced ovarian cancer. Patients take a targeted drug (olaparib) for a week before surgery, then receive heated chemotherapy directly in the abdomen during the operation. The goal is to see if this combination is safe and effective. The trial …

This expanded access program provides DNG64-CAR-V, a gene therapy, to patients with advanced pancreatic cancer, sarcoma, or breast cancer who have exhausted standard treatments. The therapy is given intravenously or directly into tumors, alone or with other cancer drugs. Early st…

This early-phase study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and understand side effects. PLB-002 is designed to target a protein (Claudin 6) found on some…

This phase 2 trial is testing two oral drugs, fuzuloparib and apatinib, given before surgery to women with a specific genetic type (HRD-positive) of advanced ovarian cancer. The goal is to shrink tumors enough for complete surgical removal, potentially improving outcomes and avoi…

This early-phase study tests a new treatment that combines specially grown immune cells (cCTL) with immunotherapy for people with advanced gynecologic cancers like ovarian, cervical, or endometrial cancer. The goal is to see if the combination is safe and can shrink tumors. About…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find…

This Phase 3 trial tests whether adding heated chemotherapy (HIPEC) directly into the abdomen during surgery can help people with advanced ovarian cancer live longer. About 520 participants who have already had some chemo will be randomly assigned to get surgery with or without H…

This early trial tests a new treatment called SY001, which uses a patient's own immune cells (macrophages) engineered to attack cancer cells that have a protein called mesothelin. The study includes just 2 people with advanced ovarian or pancreatic cancer who have not responded t…

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with ovarian cancer that no longer responds to platinum-based treatments. About 33 adults with this type of cancer will receive the combination, and researchers will measu…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This early-stage trial tests a new drug called CUSP06 for people with ovarian cancer that has stopped responding to platinum chemotherapy, as well as other advanced solid tumors. CUSP06 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells t…

This early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progresse…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This phase 2 study is testing a combination of three drugs (disitamab vedotin, carboplatin, and bevacizumab) as first treatment and ongoing therapy for women with a specific type of advanced ovarian cancer that has a protein called HER2 and lacks a repair deficiency (HRD-negative…

This study tests an experimental drug, YL205, in 252 people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and see if it helps shrink tumors. This is …

This phase II trial tests whether combining two drugs that affect cell cleanup (hydroxychloroquine and nelfinavir) with standard maintenance therapy (bevacizumab) can help keep ovarian cancer from growing back. About 38 women with recurrent high-grade serous ovarian cancer will t…

This early-stage trial is testing a one-time treatment called OPB-101 for women with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells, pl…

This phase 2 trial is testing whether a combination of two chemotherapy drugs (paclitaxel or nab-paclitaxel), an immunotherapy (pembrolizumab), and a bladder drug (mirabegron) can shrink tumors in people with ovarian cancer that has come back after initial treatment. About 20 adu…

This study tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for adults with advanced solid tumors (like breast, colon, or kidney cancer) that have not responded to standard therapies. The main goal is to check the safety of t…

This study tests a new drug called HS-20089 against standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 participants will be randomly assigned to receive either HS-20089 or…

This study tests a new drug called distamab vedotin (RC48) combined with carboplatin for people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combination works better and causes fewer side effects than standard chemotherapy. Abou…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This trial tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various rare or hard-to-treat cancers will receive …

This study tests a program called PROADAPT for women aged 70 and older with advanced ovarian cancer who need surgery. The program includes exercise, nutrition advice, education, and medication management before and after surgery. The goal is to see if it reduces serious complicat…

This study tests a new drug called YL202 in people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and control the disease. About 200 participants will receive the drug, and researchers will monitor safet…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This early-phase trial tests a personalized vaccine made from a patient's own immune cells and tumor material in 10 women with advanced ovarian cancer. The goal is to see if the vaccine can safely boost the immune system to recognize and attack cancer cells after chemotherapy. Th…

This study is testing a surgery called hepato-celiac lymphadenectomy for people with advanced or recurrent ovarian cancer. The surgery removes lymph nodes near the liver and stomach that may contain cancer. The goal is to see if this extra step, along with standard tumor removal,…

This study compares two drugs, cilastatin and thiosulfate, for protecting the kidneys in women with ovarian cancer who undergo surgery with heated chemotherapy. About 90 patients will be randomly assigned to receive one of the drugs during the procedure. The main goal is to see w…

This study tests a drug called belzutifan in people with a rare, hard-to-treat type of gynecologic cancer called clear cell carcinoma. The goal is to see if the drug can shrink tumors or stop them from growing. About 32 participants will receive the drug, and researchers will mon…

This study tests a new drug called SOA101, a special antibody that can attach to both cancer cells and immune cells to help the immune system attack tumors. It is for people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other standard treatment opt…

This study tests if two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal canc…

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This study tests whether having surgery to remove remaining tumors after chemotherapy helps people with recurrent ovarian cancer live longer. About 80 participants will be randomly assigned to either have surgery or not. The goal is to see if surgery can delay the cancer from com…

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

Researchers are comparing two ways to assess ovarian cancer risk in people who are cancer-free but may be at higher risk because of family history or genetics. One approach follows standard national guidelines, using family history and sometimes genetic testing. The other uses th…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study is testing whether an artificial intelligence (AI) tool called CAT-OV can accurately identify ovarian cancer on CT scans. Ovarian cancer is often found late, when it's harder to treat, and current screening methods aren't reliable enough. The AI is being trained and te…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study explores whether a tampon can collect DNA samples from the vagina to detect endometrial and ovarian cancer early. Researchers will compare tampon samples with tissue and blood from 1,500 women undergoing surgery. The goal is to develop a simple, non-invasive screening …

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery. The goal is to help surgeons find and remove tumors they might otherwise miss. About 170 women with suspected or recurrent ovarian cancer will take part. The study lasts about two weeks pe…

This study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy …

This study aims to improve how doctors tell the difference between borderline ovarian tumors and early-stage invasive ovarian cancer before surgery. Researchers will test a panel of nine blood-based biomarkers in 400 women with suspicious ovarian cysts. If successful, this could …

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study is testing whether combining the standard CA125 blood test with other tumor markers can help detect ovarian cancer earlier in women who are at low risk. Researchers will track 8,000 postmenopausal women over time, repeating blood tests and sometimes ultrasound if marke…

This study tests whether ultrasound images of healthy ovaries can predict if a woman carries a harmful BRCA gene mutation, which raises the risk of breast and ovarian cancers. Researchers will develop a computer model using thousands of images from women with known BRCA status. I…

This study aims to develop a screening test that uses a vaginal swab and blood sample to find DNA markers for endometrial, ovarian, and cervical cancers. Researchers at Mayo Clinic will enroll over 3,000 women to see if the test can accurately detect these cancers at an early sta…

The SENTRY study is testing whether changes in platelet RNA (a type of genetic material in blood cells) can help diagnose ovarian cancer early. Researchers will collect blood samples from 245 women—those with ovarian masses and healthy volunteers—to see if their new test can accu…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This study is testing whether a blood test that looks for tiny particles called extracellular vesicles can help detect ovarian cancer earlier. Researchers will collect blood from 1,500 postmenopausal women aged 50-74 in Queensland, Australia. The main goal is to see if the test i…

This study tests whether a specific ultrasound measurement can reliably detect superficial endometriosis on the uterosacral ligaments. Researchers will compare ultrasound findings with laparoscopic surgery results in 64 women undergoing gynecological surgery. If a clear cutoff th…

This study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…

This study tests a new ultrasound technique called microvessel imaging (UMI) to see if it can better detect small blood vessels in ovarian lesions, which may indicate cancer. Forty women scheduled for ovarian surgery will receive both standard and UMI ultrasounds. Doctors will co…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study is testing a new AI-powered blood test that looks at platelets and immune cells to find early signs of eight different cancers, including lung, breast, and pancreatic cancer. Researchers will collect blood samples from 6,000 adults aged 40 and older, both with and with…

This study tests a sentinel lymph node technique, where a small amount of radioactive tracer and dye is injected to find the first lymph nodes that might contain cancer. In 200 women with early-stage ovarian cancer, doctors will compare this method to the standard approach of rem…

This study tests whether artificial intelligence (AI) can analyze videos from a keyhole surgery (laparoscopy) to predict if ovarian cancer tumors can be completely removed. The goal is to help doctors choose the best treatment plan—surgery first or chemotherapy first—for each pat…

This study is testing whether yearly transvaginal ultrasounds can improve ovarian cancer screening in women at intermediate to high risk. Researchers aim to reduce false alarms while still catching real cancers. Up to 65,000 women in Kentucky will be screened over time to see if …

This phase 2 trial tests whether cryocompression therapy, alone or combined with the drug cilostazol, can prevent peripheral neuropathy in people receiving paclitaxel for gynecologic cancers. Peripheral neuropathy causes numbness, pain, or tingling in the hands and feet and is a …

This study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the…

This study looks at whether removing the fallopian tubes first and delaying ovary removal is as safe as removing both at once to prevent ovarian cancer in women with BRCA or other high-risk gene mutations. About 100 premenopausal women will choose either the new two-step approach…

This study looks at different preventive surgeries for women with gene mutations that raise their risk of ovarian cancer. Researchers want to see if removing the fallopian tubes first and delaying ovary removal works as well as standard surgery or close monitoring. About 480 wome…

This study is for women with BRCA1, BRCA2, or other gene mutations that greatly raise ovarian cancer risk. Instead of removing both ovaries and fallopian tubes at once, researchers are testing whether removing just the tubes first and delaying ovary removal is equally safe. The g…

This study offers free genetic testing to 5,000 women, trans men, and non-binary people with female reproductive organs, regardless of family history. The goal is to find hidden gene changes that raise the risk of breast, ovarian, bowel, and womb cancers. Participants use a smart…

This phase 2 trial tests whether drinking tart cherry juice can prevent nerve damage (neuropathy) caused by the chemotherapy drug paclitaxel in breast and ovarian cancer patients. About 86 participants will be randomly assigned to receive either a high or low dose of the juice du…

This phase 2 trial tests whether riluzole, a drug already approved for ALS, can prevent the cognitive problems (often called 'chemo brain') that many cancer patients face during chemotherapy. The study will enroll 24 adults with various cancers who are about to start chemotherapy…

This early-phase study tests whether psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce fear of cancer returning in 20 women with early-stage breast or ovarian cancer who are currently in remission. Participants receive a moderately high d…

This study tests a short therapy program called CALM (Managing Cancer and Living Meaningfully) for people with advanced ovarian cancer. The goal is to see if it is practical and helpful for reducing stress and improving well-being. Fifty participants will attend 3 to 6 therapy se…

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests a comprehensive yoga therapy program for women with advanced ovarian cancer who are scheduled for chemotherapy and surgery. The program includes dietary advice, movement, breathing exercises, and mental support. Researchers want to see if it is feasible and if it…

This study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will tak…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This pilot study tests whether a combination of stress-reducing drugs (propranolol and etodolac) and mind-body techniques (resilience training and music therapy) can help women with advanced ovarian cancer feel less stress before, during, and after surgery. The study will enroll …

This Phase 2 trial tests a drug called ASCA101 in 135 adults with solid tumors (colorectal, ovarian, or lung cancer) who have cachexia—a condition causing severe weight loss and muscle wasting. Participants receive either ASCA101, an active control (Megace), or a placebo for 12 w…

This study tests a tool called CASI that helps ovarian cancer patients, their caregivers, and doctors set a shared plan for each visit. The goal is to see if using this tool is practical and helpful. About 112 people with advanced ovarian cancer and their caregivers will take par…

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…

This study is testing whether a low dose of olanzapine, a drug usually used for mental health conditions, can prevent or treat the loss of appetite and weight that often happens in cancer patients receiving chemotherapy. About 100 adults with stomach or ovarian cancer will take t…

This study tests whether using cold wraps plus compression (cryocompression) on hands and feet during chemotherapy can reduce nerve damage (peripheral neuropathy) in people with gynecologic cancer. About 190 participants will be randomly assigned to receive either cryocompression…

This study tests whether a 4-week exercise program before surgery can reduce frailty and improve recovery in women with advanced ovarian cancer. Frailty affects about half of these patients and often leads to worse surgical outcomes and chemotherapy delays. The program includes l…

This study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study tests whether a 30-minute moderate cycling session just before chemotherapy or immunotherapy can help cancer patients maintain their fitness. 80 adults with breast, ovarian, or colorectal cancer will either receive standard advice or also exercise with a physiotherapis…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study tests a coaching program called POSTCARE-O for women with ovarian cancer who have finished their initial treatment. The program provides support during the transition to survivorship, focusing on quality of life and emotional well-being. 120 women will be randomly assi…

This study tests a 4-week online cognitive-behavioral therapy (CBT) program for women with BRCA1/2 mutations who have finished cancer treatment and still worry a lot about cancer coming back. Researchers will compare those who get therapy right away to those on a waitlist, measur…

This study tests whether live, group-based exercise classes held over Zoom can help cancer survivors increase their physical activity, improve fitness, and enhance quality of life. Researchers will randomly assign 300 cancer survivors to either live online classes or recorded exe…

This study looks at whether alternate day fasting (eating very little every other day) before chemotherapy can help reduce side effects and improve quality of life for women with ovarian, endometrial, or uterine cancer. About 30 women who have had surgery and are about to start c…

This study tests whether a program of exercise, nutrition advice, and mental support before surgery helps gynecological cancer patients recover faster and feel better. About 64 women with ovarian or endometrial cancer will be randomly assigned to either standard care or the preha…

This study tests whether adding a gentle electrical acupoint stimulation (TEAS) to a standard three-drug anti-nausea regimen can further reduce vomiting after laparoscopic surgery. Researchers will compare active TEAS to a sham (fake) version in 780 women at high risk for postope…

This study explores whether acupuncture can reduce nerve pain and numbness caused by chemotherapy in people with gynecologic, urologic, or rectal cancers. About 75 participants will be randomly assigned to receive real acupuncture, sham acupuncture, or usual care for 6 weeks. The…

This study tests whether a 16-week, virtually supervised exercise program can help patients with ovarian or endometrial cancer maintain leg function and reduce chemotherapy-induced nerve damage. Thirty patients who have had surgery and are starting first-line chemo will be assign…

This study tests whether a personalized physical activity program using a wearable device (like a Fitbit) can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either receive tailored activity goals and fee…

This study tests whether a mobile cognitive training app can reduce 'chemobrain'—memory and thinking problems caused by chemotherapy—in people with gynecologic cancers. Sixty-four participants will use the app on their own phones while undergoing chemotherapy and complete thinkin…

This study tests whether a non-invasive device that gently stimulates a nerve in the ear can improve quality of life by reducing digestive symptoms like nausea and bloating during first-line chemotherapy for ovarian cancer. About 116 women will be randomly assigned to receive eit…

This study tests whether a pre-surgery program of exercise and a dietary supplement called Ocoxin can improve recovery for 100 women undergoing surgery for gynecologic cancers like endometrial, ovarian, or cervical cancer. Participants will follow an enhanced recovery protocol (E…

Researchers at the University of New Mexico collect ascites fluid, the liquid that builds up in the abdomen, from women undergoing surgery for ovarian cancer. They study this fluid and tumor tissue in the lab to learn how the tumor environment helps cancer spread within the perit…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FR…

This study looks at whether preserving the left colic artery during colon or rectal cancer surgery helps keep the remaining colon well-supplied with blood. Surgeons will temporarily clamp the main artery and use a green dye to measure blood flow. The goal is to see if this techni…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal …

This study looks at whether a blue dye injected into the ovary can help doctors find the first lymph node where cancer might spread, instead of removing many lymph nodes. The goal is to see if this less invasive method works as well as standard surgery for early-stage ovarian can…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…

This observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study looks at how neoadjuvant chemotherapy (given before surgery) affects thinking skills like memory and attention in people with advanced ovarian cancer. Researchers will test 18 participants using questionnaires and cognitive tests over about 10 months. The goal is to be…

This study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study gathers medical records and leftover tissue samples from up to 2,000 people with low-grade ovarian or peritoneal tumors. The goal is to create a detailed database that helps researchers learn more about these rare cancers and how they are treated. No new drugs or proce…

This study looks at whether older adults with gynecologic cancer are willing to complete physical and cognitive tests before and after treatment. Researchers will also take small muscle and blood samples to study how cell energy relates to resilience. The goal is to see if this k…

This study looks at tissue samples from 200 people with relapsed ovarian, fallopian tube, or primary peritoneal cancer to see how often a protein called folate receptor alpha (FRα) is present at high levels. The goal is to understand how common this protein is, which may help doc…

This study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…

This study looks at genetic targets in ovarian cancer, focusing on a common type called high-grade serous carcinoma. Researchers will analyze tumor tissue from 180 adult women to understand which genes are involved. The goal is to find new ways to diagnose or treat the disease, b…

This study aims to create and improve educational materials about genetic testing for cancer patients from diverse backgrounds. Researchers will interview 445 people with breast, ovarian, pancreatic, prostate, or colorectal cancer who speak English, Spanish, or Haitian Creole. Th…

This study looks at whether giving chemotherapy before surgery helps older adults (over 55) with advanced ovarian or endometrial cancer become fitter for their operation. Researchers will measure changes in frailty using a special score from medical records. The goal is to see if…

This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will re…

This study surveys 2,000 ovarian cancer survivors to identify their ongoing concerns and unmet needs after diagnosis. Participants complete a one-time survey about their experiences, and up to 40 will also take part in a follow-up interview. The goal is to understand what matters…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…

This observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …

This study tests a workshop called HOPE-C, designed to reduce burnout among doctors, nurses, and social workers who care for ovarian cancer patients. The workshop helps clinicians share their challenging stories and build peer support. Researchers will enroll 25 participants to s…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study looks at whether a family history screening program can help more women in rural public health clinics get tested for genetic risks linked to breast and ovarian cancer. About 3,200 women over age 25 will take part. The goal is to see if the program increases the number…

This pilot study is testing whether a 7-day integrative oncology retreat called 'Via Shalva' is practical and helpful for women who have finished primary treatment for breast or gynecologic cancer. Thirty participants will either attend the retreat or receive usual follow-up care…

This study aims to find women in Texas who are at risk for hereditary breast, ovarian, and colorectal cancers but have limited access to healthcare. Researchers will use mobile mammography units to offer genetic testing and counseling on the spot. Up to 1,000 women will provide a…

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study collects tumor and blood samples from 3,300 people at high genetic risk for breast, ovarian, and related cancers. Researchers want to learn how these cancers develop and how well treatments work. Participants include those with BRCA1/2 or other gene mutations, or a str…

This early-stage study tests a small implantable device that is placed directly into tumors to see how different drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will receive the device during standard surgery. The goal is t…

Cancer patients face a higher risk of blood clots during chemotherapy, but it's hard to know who is most at risk. This study will measure clotting-related biomarkers in the blood of 380 patients with ovarian, lung, stomach, or pancreatic cancer at four points during their treatme…

This pilot study tests whether an AI-based system can help doctors better manage fluids and blood pressure during complex ovarian cancer surgery. The system uses special software to guide fluid infusions and predict drops in blood pressure. The goal is to reduce complications lik…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study takes tumor samples from people with triple-negative breast cancer, colorectal cancer, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to provide person…

This study follows 200 women with gynecologic cancer and their partners to see how sexual function changes over time. Researchers use questionnaires at diagnosis, 6 months, and 12 months after treatment. The goal is to understand when sexual counseling might be most helpful, with…

This study is looking at how the immune system responds to breast and ovarian cancers. Researchers will analyze tumor and blood samples from 160 women before surgery to understand immune cell activity and find markers that might predict survival. The goal is to learn more about h…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study looks at 50 patients with ovarian cancer that has come back quickly (within 6 months). Researchers will track their health and survival to learn more about who responds best to treatment. The goal is to improve how doctors classify and care for these patients.

This study aims to collect and analyze genetic information from 300 Taiwanese women with ovarian cancer. Researchers will look at tumor samples and medical records to find gene changes linked to treatment response and survival. The goal is to build a database that helps develop p…

This study looks at 371 people with advanced ovarian, peritoneal, or fallopian tube cancer to find out what factors—like age, tumor type, and genetics—are linked to how long they live. Researchers will collect medical data and blood samples over two years. The goal is to build a …

This study will analyze the genes of 25,000 adults who have cancer or are at risk for it. Researchers will use advanced testing to find genetic changes linked to cancer and track health records over time. The goal is to learn more about cancer biology and discover new ways to per…

This study collects tumor, fluid, blood, and other samples from 350 ovarian cancer patients to find biological markers that predict how the disease will respond to treatment. Researchers will analyze genetic changes before and after therapy to understand why some cancers become r…

This study tests whether a computer-generated character (PERLA) can effectively educate cancer patients about genetic testing, compared to a human genetics counselor. Researchers will enroll 800 people with certain cancers, including breast, ovarian, pancreatic, and prostate canc…

This study is looking for better ways to predict who might develop or have a return of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will collect blood samples from 850 participants to study genetic and other biological markers. The goa…

This study is creating a new survey to better understand how cancer and its treatments affect daily life. Researchers will ask 1,000 adults with cancer about their quality of life over two years. The goal is to help doctors and families provide better support tailored to each pat…

This study is testing whether a polygenic risk score (PRS) — a calculation based on many small genetic variations — can help predict a woman's chance of developing ovarian cancer. Researchers will compare the PRS of 1,300 Italian women, half with ovarian cancer and half without. …

This study follows 1,000 women newly diagnosed with epithelial ovarian cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Researchers will track surgery outcomes, treatment response, and survival. The goal is to gather r…

This study follows 50 women aged 70 and older with advanced ovarian cancer who are starting PARP inhibitors for the first time. Researchers will track how much of the planned dose patients actually receive, and look at factors like age, genetics, and overall health that might aff…

This study is gathering information from 25 adults with breast, lung, ovarian, multiple myeloma, or acute myeloid leukemia who are on active treatment. Participants fill out a short online survey each week for at least 12 weeks to report how they are feeling. The goal is to build…

This study is testing whether a web and mobile phone program can help Hispanic women who have had breast, uterine, or ovarian cancer, along with their adult daughters, eat better and be more active. The program includes 8 online modules. The main goal is to see if the program is …

This study aims to understand why some ovarian cancer patients respond well to platinum-based chemotherapy for years, while others do not respond at all. Researchers will analyze genetic, clinical, and tissue samples from 55 patients treated at one center. The goal is to find dif…

This study is testing a new blood test that looks for tumor DNA (ctDNA) to see if it can find ovarian cancer coming back earlier than current methods like CT scans or CA-125 blood tests. About 30 women with advanced ovarian cancer will give blood samples over time during their fo…

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…

This study looks at the bacteria and natural chemicals in the vagina to see if they can help find ovarian cancer early. Healthy volunteers (people with ovaries but no cancer or genetic risk) will provide vaginal swabs and stool samples. Their samples will be compared to those fro…

This study collects tumor and blood samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). Researchers will analyze the samples to find links between genetic changes, the immune system, and how the cancer behaves. Parti…

This study follows 600 Japanese women who carry BRCA1 or BRCA2 gene changes to see how often they develop ovarian, fallopian tube, or peritoneal cancers. Participants are monitored over time, and researchers also check tissue samples from those who choose preventive surgery. The …

This study is a large German registry that will follow nearly 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease responds, and their quality of life. The goal is to understa…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study looks at whether a special hospital visit with a team of experts can help women who finished treatment for ovarian or endometrial cancer get more of the supportive care they need. About 268 women in remission will be split into groups: some get the extra hospital asses…

This study compares two common risk assessment tools—the Charlson Comorbidity Index (CCI) and the POSSUM score—to see which better predicts complications in women undergoing surgery for gynecologic cancers. Researchers will track complications, hospital stay length, and 30-day de…

This study aims to understand why the immune system fails to fight ovarian cancer effectively. Researchers will compare blood, bone marrow, and immune cells from 90 women with ovarian cancer and healthy controls. The goal is to find ways to reprogram immune cells to attack the tu…

This study aims to learn how gene and protein changes in gynecologic tumors affect cancer behavior and treatment response. Researchers will collect tumor tissue and blood samples from 1,000 people with ovarian, uterine, cervical, or other gynecologic cancers. The goal is to bette…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study tracks 100 cancer survivors aged 18–74 to see how common muscle loss (sarcopenia) and cognitive problems ('chemo brain') are after treatment. Participants undergo physical and mental assessments. The goal is to better understand these long-term side effects and guide p…

This study looks at whether a blood test can find genetic changes in tumor DNA that signal ovarian cancer is coming back. It involves 130 women with BRCA mutations who are taking a maintenance drug called Olaparib after initial treatment. The goal is to see if these blood tests c…

This study looks at whether it is safe to avoid creating a temporary stoma (a bag on the belly to collect stool) after removing part of the bowel during surgery for advanced ovarian cancer. About 395 women at low risk for bowel leaks will be followed to see how often leaks happen…

This study is testing two genetic tests (Giscar and myChoice) to see if they can identify ovarian cancer patients whose tumors have a specific DNA repair problem (HRD). The goal is to see if these tests can predict which patients will respond well to platinum chemotherapy and may…

This study looks at whether a quick ultrasound of the thigh muscle can detect muscle loss (sarcopenia) in people who have finished cancer treatment. Researchers will compare the ultrasound results with a standard whole-body scan (DEXA) in 55 adults aged 18-74 with certain cancers…

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…